Levetiracetam (All indications) updated on 04-22-2025

ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19378
R82481
Straub (Controls exposed to LTG) (Levetiracetam) (Epilepsy), 2026 Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.56 [0.41;0.76] C
excluded (control group)
69/3,929   102/3,273 171 3,929
ref
S19369
R82488
Straub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes 0.89 [0.68;1.17] 69/3,929   366/8,887 435 3,929
ref
S17414
R73067
Madley-Dowd_SE (Levetiracetam) (Controls exposed to LTG) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes Partial overlapping 1.18 [0.69;2.02]
excluded (control group)
14/613   243/5,035 257 613
ref
S17415
R73071
Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Partial overlapping 1.02 [0.60;1.72] 14/613   147,608/2,651,210 147,622 613
ref
S17416
R73075
Madley-Dowd_SE (Levetiracetam) (Controls unexposed, sibling) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective sibling excluded Adjustment: Yes Partial overlapping 1.06 [0.30;3.77]
excluded (control group)
-/-   -/- - -
ref
S17282
R72366
Madley-Dowd_UK (Levetiracetam) (Controls exposed to LTG) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.19 (2.56-6.79) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.90 [0.16;5.10]
excluded (control group)
-/193   14/939 - 193
ref
S17267
R72367
Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.19 (2.56-6.79) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.48 [0.28;7.83] -/193   4,794/514,066 - 193
ref
S17275
R72368
Madley-Dowd_UK (Levetiracetam) (Controls unexposed, sibling) (Mixed indications), 2024 Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.19 (2.56-6.79) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) sibling excluded Adjustment: Yes 4.06 [0.52;31.68]
excluded (control group)
-/-   -/- - -
ref
S15238
R63062
Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.73 [0.42;1.29] C
excluded (control group)
14/1,061   95/5,288 109 1,061
ref
S15230
R63063
Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 1.78 [1.03;3.07] 14/1,061   528/22,203 542 1,061
ref
S9022
R46401
Huber-Mollema (Levetiracetam), 2019 Diagnosis of ADHD throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 0.25 [0.01;4.74] C 0/30   5/88 5 30
ref
S9018
R46402
Bromley (Levetiracetam), 2016 Maladaptive behavior: Attention (BASC) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No extrapolated (cont. endpoint) 0.86 [0.41;1.78] -/42   -/55 - 42
ref
Total 6 studies 1.04 [0.79;1.37] 148,604 5,868
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Straub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026Straub, 2026 1 0.89[0.68; 1.17]4353,92945%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_SE, 2024 2 1.02[0.60; 1.72]147,62261320%ROB confusion: seriousROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK, 2024 3 1.48[0.28; 7.83]-1933%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 4 1.78[1.03; 3.07]5421,06119%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Huber-Mollema (Levetiracetam), 2019Huber-Mollema, 2019 5 0.25[0.01; 4.74]5301%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Bromley (Levetiracetam), 2016Bromley, 2016 6 0.86[0.41; 1.78]-4212%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (6 studies) I2 = 20% 1.04[0.79; 1.37]148,6045,8680.25.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick) (Levetiracetam) (Epilepsy; 2: Levetiracetam) (Controls unexposed, general pop) (Mixed indications; 3: Levetiracetam) (Controls unexposed, general pop) (Mixed indications; 4: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 5: Levetiracetam; 6: Levetiracetam;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.04[0.79; 1.37]148,6045,86820%NAStraub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Huber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 6 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.06[0.64; 1.74]147,6228060%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 2 unexposed, sickunexposed, sick 1.09[0.69; 1.73]9775,03261%NAStraub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Levetiracetam), 2016 3 exposed to other treatment, sickexposed to other treatment, sick 0.25[0.01; 4.74]530 -NAHuber-Mollema (Levetiracetam), 2019 1 Tags Adjustment   - No  - No 0.80[0.39; 1.63]5720%NAHuber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 2   - Yes  - Yes 1.12[0.79; 1.59]148,5995,79642%NAStraub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 4 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.86[0.41; 1.79]-42 -NABromley (Levetiracetam), 2016 1 Partial overlappingPartial overlapping 1.02[0.60; 1.73]147,622613 -NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 1 All studiesAll studies 1.04[0.79; 1.37]148,6045,86820%NAStraub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Huber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 60.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.53.61.7910.000Straub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026Madley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023Huber-Mollema (Levetiracetam), 2019Bromley (Levetiracetam), 2016

Asymetry test p-value = 0.8510 (by Egger's regression)

slope=-0.0340 (0.2369); intercept=0.1817 (0.9068); t=0.2003; p=0.8510

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 15238, 17414, 17416, 17282, 17275, 19378

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.06[0.64; 1.74]152,4078060%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, general pop) (Mixed indications), 2024 2 unexposed, sick controlsunexposed, sick controls 1.09[0.69; 1.73]9775,03261%NAStraub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Levetiracetam), 2016 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.73[0.51; 1.06]5475,82636%NAStraub (Controls exposed to LTG) (Levetiracetam) (Epilepsy), 2026 Madley-Dowd_SE (Levetiracetam) (Controls exposed to LTG) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls exposed to LTG) (Mixed indications), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 Huber-Mollema (Levetiracetam), 2019 5 siblingssiblings 1.61[0.48; 5.44]--16%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sibling) (Mixed indications), 2024 Madley-Dowd_UK (Levetiracetam) (Controls unexposed, sibling) (Mixed indications), 2024 20.510.01.0